Chemistry & Process Engineering forum Rapid.Tech 3D 2024

New additive paths in pharmaceutical production and galenics - serial multi-active ingredient tablet production

Dr Gereon Heinemann, CEO of Exentis Group AG, will give his presentation at the specialist congress on the topic of "New paths in pharmaceutical production and galenics - serial multi-active ingredient tablet production"

What does additive manufacturing have in common with galenics? With its comprehensively patented additive manufacturing technology, Exentis can print tablets with completely new properties and a freely selectable active ingredient release profile. Imagine a multi-active ingredient production process that allows the manufacture of tablets in which the release of the individual active ingredients is staggered. This is what we mean by innovation: a combination of our 3D screen printing technology and direct added value for the individual patient.
Exentis has optimised its additive manufacturing technology for any cleanroom application in a modular system for pharmaceutical applications. This allows up to 3 different active ingredients to be processed on one system and up to 200 million tablets to be produced per year. A first cleanroom system was successfully installed and commissioned at a CDMO in April 2024 - find out for yourself what is possible with Exentis systems.

Presentation language: GER
(English translation will be provided on site)


Speakers (1)

Dr. Gereon Heinemann

Dr. Gereon Heinemann

CEO - Chief Executive Officer